Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
03 janv. 2025 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate...
Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update
02 janv. 2025 16h05 HE
|
Lifecore Biomedical, Inc.
-- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 -- -- Signed Multiple Development Agreements with New Customers -- -- Strengthened Balance Sheet with Financing Raising Approximately $24.3...
BioStem Technologies CEO to Present at Biotech Showcase 2025
02 janv. 2025 07h00 HE
|
BioStem Technologies, Inc.
BioStem Technologies CEO to Present at Biotech Showcase 2025
2024 Rising Stars Shine at iC³ Summit: Celebrating Progress and Setting the Stage for 2025
30 déc. 2024 10h59 HE
|
BioNTX
DALLAS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- The 2024 Rising Stars of the life sciences and healthcare innovation sector took center stage at the iC³ Life Science Summit this year, marking another...
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
26 déc. 2024 09h00 HE
|
FN Media Group LLC
PALM BEACH, Fla., Dec. 26, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the diverse applications of drugs in...
XBiotech Pauses Rheumatology program
23 déc. 2024 09h00 HE
|
XBiotech Inc.
AUSTIN, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data that it is halting its clinical program in rheumatological disease while it seeks to understand the...
Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
23 déc. 2024 07h30 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has validated the Marketing...
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
20 déc. 2024 00h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize...
NTHU Researchers Unveil the Mystery of Cancer Cells' Sugar Addiction
19 déc. 2024 10h00 HE
|
NATIONAL TSING HUA UNIVERSITY
NTHU researchers uncover how cancer cells’ sugar addiction fuels growth, paving the way for potential new cancer treatments.
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
19 déc. 2024 06h38 HE
|
Ocugen
OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular...